

KURZPROTOKOLL
IBIS

Öffentlicher Titel	Inzidenz und wirtschaftliche Belastung von Clostridium-Difficile-Infektionen (CDI) im deutschen Gesundheitswesen
Wissenschaftl. Titel	Incidence and Economic Burden of Community and Hospital- Acquired Clostridium Difficile Infections (CDI) in the German Health Care System (IBIS)
Kurztitel	IBIS
Studienart	multizentrisch, prospektiv, offen/unverblindet, einarmig, Register, nicht-interventionelle Studie, Investigator Initiated Trial (IIT)
Studienphase	nicht zutreffend
Erkrankung	Infektionen: Bakterielle Infektionen
Einschlusskriterien	- Index episode of CDI based on: - the presence of diarrhea (defined as ≥ 3 unformed bowel movements/24h) plus - an enzyme immunoassay (EIA) detecting Glutamate dehydrogenase (GDH) or polymerase chain reaction (PCR) for toxin B test plus - a positive EIA for toxin A and B - Ongoing or new hospitalization at inclusion into the study - Written informed consent (IC) has been obtained from the study subject or a legal representative
Ausschlusskriterien	- Patient with any social or logistical condition which in the opinion of the investigator may interfere with the conduct of the study, such as incapacity to well understand, not willing to collaborate, or cannot easily be contacted after discharge - CDI episode within the previous 84 days
Alter	18 Jahre und älter
Prüfzentren	Innere Medizin 2 (Geschlossen) Infektiologie Theodor-Stern-Kai 7 60590 Frankfurt am Main Prof. Dr. med. Maria Vehreschild Tel: 069 6301 5452 Fax: 069 6301 6378 maria.vehreschild@unimedizin-ffm.de
Sponsor	Universitätsklinikum Köln
Förderer	Universitätsklinikum Köln
Registrierung in anderen Studienregistern	ClinicalTrials.gov NCT03141775 (primäres Register)